MCID: INF023
MIFTS: 48

Inflammatory Breast Carcinoma

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 15 17 70
Inflammatory Breast Cancer 73 20 54
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 44
Breast Cancer, Inflammatory 20
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 44 D058922
NCIt 50 C4001
SNOMED-CT 67 254840009
UMLS 70 C0278601

Summaries for Inflammatory Breast Carcinoma

GARD : 20 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called "inflammatory" because the breast often looks swollen and red, or "inflamed." The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions.

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to female breast cancer and linitis plastica, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Actin Nucleation by ARP-WASP Complex. The drugs Progesterone and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and lung, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Disease Ontology : 12 A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.

Wikipedia : 73 Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. It can occur at... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 female breast cancer 29.9 PGR ESR1 ERBB2
2 linitis plastica 29.6 PGR ERBB2 CDH1
3 fallopian tube carcinoma 29.6 PGR ESR1 ERBB2
4 gynecomastia 29.6 PGR ESR1 ERBB2
5 lymphangioma 29.6 PROX1 LYVE1 EGFR
6 suppression of tumorigenicity 12 29.4 ERBB2 EGFR CDH1
7 breast disease 29.2 RHOC PGR ESR1 ERBB2
8 colon adenocarcinoma 29.2 ESR1 ERBB2 EGFR CDH1
9 pleomorphic carcinoma 29.2 PGR EGFR
10 lung cancer susceptibility 3 29.1 VEGFD ERBB2 EGFR CDH1
11 ovary adenocarcinoma 28.8 PGR ESR1 ERBB2 EGFR CDH1
12 in situ carcinoma 28.8 PGR ESR1 ERBB2 EGFR CDH1
13 ductal carcinoma in situ 28.7 PGR ESR1 ERBB2 EGFR CDH1
14 cervix carcinoma 28.7 PGR ESR1 ERBB2 EGFR CDH1
15 esophageal cancer 28.6 VEGFD MIR203A ERBB2 EGFR CDH1
16 breast ductal carcinoma 28.6 VEGFD PGR ESR1 ERBB2 EGFR CDH1
17 gastric cancer 27.9 VEGFD PGR MIR203A ESR1 ERBB2 EGFR
18 mastitis 10.4
19 neutropenia 10.3
20 acquired hemangioma 10.3 PROX1 LYVE1
21 intramuscular hemangioma 10.3 PROX1 LYVE1
22 capillary lymphangioma 10.3 PROX1 LYVE1
23 lymphangiosarcoma 10.3 PROX1 LYVE1
24 mucositis 10.2
25 breast cystic hypersecretory carcinoma 10.2 ERBB2 CDH1
26 trichorhinophalangeal syndrome, type i 10.2 ESR1 CDH1
27 esophageal adenosquamous carcinoma 10.2 ERBB2 CDH1
28 ovarian cancer 10.2
29 47,xyy 10.2
30 bartholin's gland adenoma 10.2 PGR ESR1
31 bartholin's gland adenoid cystic carcinoma 10.2 PGR ESR1
32 uterine corpus adenosarcoma 10.2 PGR ESR1
33 bartholin's gland benign neoplasm 10.2 PGR ESR1
34 chronic tympanitis 10.2 PGR ESR1
35 vestibular gland benign neoplasm 10.2 PGR ESR1
36 granulomatous endometritis 10.2 PGR ESR1
37 vulvar syringoma 10.1 PGR ESR1
38 hypotrichosis-lymphedema-telangiectasia syndrome 10.1 PROX1 LYVE1
39 lung leiomyoma 10.1 PGR ESR1
40 adult type testicular granulosa cell tumor 10.1 PGR ESR1
41 cervical clear cell adenocarcinoma 10.1 PGR ESR1
42 ovarian seromucinous carcinoma 10.1 PGR ESR1
43 liver leiomyoma 10.1 PGR ESR1
44 intravenous leiomyomatosis 10.1 PGR ESR1
45 intracranial meningioma 10.1 PGR ESR1
46 vulvar leiomyoma 10.1 PGR ESR1
47 bizarre leiomyoma 10.1 PGR ESR1
48 breast adenoma 10.1 PGR ESR1
49 prostate stromal sarcoma 10.1 PGR ESR1
50 capillary hemangioma 10.1 PROX1 LYVE1

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema; pain; peau d'orange

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.86 CDH1 EGFR ERBB2 ESR1 LYVE1 PGR
2 endocrine/exocrine gland MP:0005379 9.7 CCN6 CDH1 EGFR ERBB2 ESR1 PGR
3 neoplasm MP:0002006 9.56 CCN6 CDH1 EGFR ERBB2 ESR1 PGR
4 normal MP:0002873 9.23 CCN6 CDH1 EGFR ERBB2 ESR1 PGR

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
Melphalan Approved Phase 3 148-82-3 4053 460612
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Palonosetron Approved, Investigational Phase 3 135729-56-5, 119904-90-4 148211
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
11
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
13
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
14
Fosaprepitant Approved Phase 3 172673-20-0 219090
15
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
16
Prochlorperazine Approved, Vet_approved Phase 3 1984-02-6, 58-38-8 4917
17
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
18
Busulfan Approved, Investigational Phase 3 55-98-1 2478
19
Epirubicin Approved Phase 3 56420-45-2 41867
20
Fluorouracil Approved Phase 3 51-21-8 3385
21
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
22
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
23
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
24
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
25
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
26
Sodium citrate Approved, Investigational Phase 3 68-04-2
27
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
28
Tamoxifen Approved Phase 3 10540-29-1 2733526
29
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
30
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
32 Folic Acid Antagonists Phase 3
33 Dermatologic Agents Phase 3
34 taxane Phase 3
35 Protein Kinase Inhibitors Phase 2, Phase 3
36 Psychotropic Drugs Phase 3
37 Dopamine Antagonists Phase 3
38 Gastrointestinal Agents Phase 3
39 Neurotransmitter Agents Phase 3
40 Antiemetics Phase 3
41 Serotonin 5-HT3 Receptor Antagonists Phase 3
42 Neurokinin-1 Receptor Antagonists Phase 3
43
Substance P Phase 3 33507-63-0 44359816
44 Dopamine Agents Phase 3
45 glucocorticoids Phase 3
46 Anti-Inflammatory Agents Phase 3
47 BB 1101 Phase 3
48 Antipsychotic Agents Phase 3
49 neurokinin A Phase 3
50 Aromatase Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regimen Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
3 A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
4 First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
5 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
6 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
7 A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
8 Phase III Trial Assessing the Interest of a Maintenance Chemotherapy Combining Docetaxel (Taxotere) 5-FU After Induction Treatment by Aintensive Chemotherapy for Inflammatory Breast Cancers Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
9 A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer Completed NCT00003972 Phase 3 busulfan;carboplatin;cyclophosphamide;melphalan;paclitaxel;tamoxifen citrate;thiotepa
10 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
11 A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) Completed NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
12 A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
13 A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
14 A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer Active, not recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
15 Conservative Local Treatment Versus Mastectomy After Induction Chemotherapy In Locally Advanced Breast Cancer: A Randomized Phase III Study Terminated NCT00028704 Phase 3
16 A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
17 Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer Withdrawn NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
18 Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON] Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
19 PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH HIGH RISK STAGE II AND III BREAST CANCER Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
20 Phase II Neoadjuvant Trial of Docetaxel (Taxotere), Carboplatin, and Capecitabine (Xeloda) in the Treatment of Early Stage Locally Advanced and Inflammatory Breast Cancer Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
21 Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer Unknown status NCT02041429 Phase 1, Phase 2 Ruxolitinib;Paclitaxel
22 Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer Unknown status NCT01796197 Phase 2 Trastuzumab;Pertuzumab;Paclitaxel;Doxorubicin;Cyclophosphamide
23 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
24 Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer Completed NCT00820547 Phase 2 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
25 A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
26 Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer Completed NCT00943410 Phase 2 Herceptin
27 A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
28 Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
29 Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
30 A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
31 Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Stg IV Breast Cancer w/4 Cycles of Adriamycin and Cytoxan (AC),Followed by 12 Weeks of Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Wkly Herceptin or no Additional Therapy Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
32 A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
33 A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
34 A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer Completed NCT00450892 Phase 1, Phase 2 docetaxel+lapatinib;docetaxel + trastuzumab;docetaxel + trastuzumab + lapatinib
35 Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
36 Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
37 A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer Completed NCT00513695 Phase 2 sunitinib malate;paclitaxel;doxorubicin hydrochloride;cyclophosphamide
38 A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
39 Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) Completed NCT03742986 Phase 2 Nivolumab 360mg;Paclitaxel 80mg/m^2;Doxorubicin 60mg/m^2;Cyclophosphamide 600mg/m^2;Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2;Trastuzumab 8mg/kg and 6 mg/kg;Pertuzumab 840mg and 420mg
40 An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
41 A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse Completed NCT01262027 Phase 2 Dovitinib
42 A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
43 Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
44 A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
45 A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
46 A Pilot Study to Evaluate Angiogenesis After Treatment With Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients With Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
47 Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
48 A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC) Completed NCT03184558 Phase 2 Bemcentinib; pembrolizumab
49 A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer Completed NCT00916578 Phase 2 Capecitabine
50 Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study Completed NCT00254592 Phase 2 Doxorubicin;Cyclophosphamide;Carboplatin;Nab-paclitaxel;GM-CSF;Trastuzumab;Bevacizumab

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

40
Breast, Lymph Node, Lung, Cervix, Skin, Endothelial, Ovary

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 1418)
# Title Authors PMID Year
1
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 61 54
20406946 2010
2
Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients. 54 61
20014943 2010
3
Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. 54 61
20395207 2010
4
Biology and management of inflammatory breast cancer. 61 54
20131997 2010
5
Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. 61 54
19675678 2009
6
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. 54 61
19394894 2009
7
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. 54 61
19228416 2009
8
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. 54 61
18821931 2008
9
The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer. 54 61
18704635 2008
10
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. 61 54
18321996 2008
11
Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. 61 54
18366705 2008
12
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. 54 61
18212337 2008
13
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 54 61
18202008 2008
14
NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. 54 61
17700572 2007
15
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. 54 61
17351259 2007
16
Vascular endothelial growth factor-C in patients with breast cancer. 61 54
17591368 2007
17
Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. 61 54
16932944 2007
18
CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. 61 54
17587813 2007
19
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. 61 54
16755113 2006
20
[Biological significance of E-cadherin in an inflammatory breast carcinoma cell line]. 61 54
16737610 2006
21
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. 61 54
16187229 2005
22
Occult inflammatory breast cancer: review of clinical, mammographic, US and pathologic signs. 54 61
15883516 2005
23
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. 61 54
15585631 2004
24
High incidence of HER-2 positivity in inflammatory breast cancer. 61 54
15019688 2004
25
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. 61 54
15140407 2004
26
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. 54 61
15023242 2004
27
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. 61 54
14696649 2004
28
Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002. 61 54
14506176 2003
29
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. 54 61
12618881 2003
30
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. 54 61
12473600 2002
31
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. 61 54
12386822 2002
32
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. 61 54
12479217 2002
33
[Establishment and characterization of human inflammatory breast carcinoma neoplasm transplantation in nude mice]. 54 61
16201199 2001
34
Persistent E-cadherin expression in inflammatory breast cancer. 54 61
11353057 2001
35
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? 54 61
10673516 2000
36
A novel human xenograft model of inflammatory breast cancer. 61 54
10537277 1999
37
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. 54 61
10499627 1999
38
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. 61 54
10551327 1999
39
Metaplastic breast carcinoma: a cytohistologic and clinical study of 10 cases. 54 61
8732652 1996
40
The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. 61
32974693 2021
41
Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy. 61
33560188 2021
42
Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum. 61
33535154 2021
43
MicroRNAs Involved in Inflammatory Breast Cancer: Oncogene and Tumor Suppressors with Possible Targets. 61
33493414 2021
44
Inflammatory Breast Cancer in Men: A rare clinical case report and a literature review. 61
33667907 2021
45
Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma. 61
33550148 2021
46
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells. 61
33616115 2021
47
Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer? 61
33364047 2021
48
Pruritic breast mass with palpable lymph nodes in a male patient: a case report. 61
33708564 2021
49
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis. 61
33549037 2021
50
Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer. 61
32800492 2021

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 VEGFD ESR1 ERBB2 EGFR CDH1
2
Show member pathways
12.69 RHOC ERBB2 EGFR CDH1
3 12.49 VEGFD ESR1 ERBB2 EGFR CDH1
4
Show member pathways
12.4 ESR1 ERBB2 EGFR CDH1
5
Show member pathways
12.32 PGR ESR1 ERBB2 EGFR CDH1
6
Show member pathways
12.02 VEGFD RHOC ERBB2 EGFR CDH1
7 11.91 ESR1 EGFR CDH1
8 11.83 PGR ESR1 EGFR
9
Show member pathways
11.81 RHOC ERBB2 EGFR CDH1
10 11.69 RHOC EGFR CDH1
11
Show member pathways
11.62 ESR1 ERBB2 EGFR
12 11.5 ERBB2 EGFR CDH1
13 11.46 ERBB2 EGFR CDH1
14 11.05 ERBB2 EGFR
15
Show member pathways
10.96 PGR ESR1 ERBB2 EGFR
16 10.8 EGFR CDH1
17 10.71 VEGFD RHOC ERBB2 EGFR CDH1
18 10.62 ERBB2 EGFR CDH1

GO Terms for Inflammatory Breast Carcinoma

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.62 VEGFD PROX1 ERBB2 EGFR
2 positive regulation of protein kinase B signaling GO:0051897 9.43 ESR1 ERBB2 EGFR
3 steroid hormone mediated signaling pathway GO:0043401 9.16 PGR ESR1
4 intracellular steroid hormone receptor signaling pathway GO:0030518 8.96 PGR ESR1
5 negative regulation of ERBB signaling pathway GO:1901185 8.62 ERBB2 EGFR

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 VEGFD PGR ESR1 ERBB2 EGFR CDH1
2 steroid binding GO:0005496 9.32 PGR ESR1
3 steroid hormone receptor activity GO:0003707 9.26 PGR ESR1
4 ATPase binding GO:0051117 9.13 PGR ESR1 EGFR
5 nitric-oxide synthase regulator activity GO:0030235 8.62 ESR1 EGFR

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....